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Objective: To ascertain the prevalence of hepatitis C virus (HCV) genotypes in Spain and their distribution by risk factors. 
Methods: The study covered 216 patients with hepatitis C. Of these, 63 were intravenous drug users (IVDU), 44 had 
received transfusions, and 30 were hemodialyzed, and in 79 the risk factors were unknown. Antibodies against HCV were 
detected by second-generation enzyme immunoassay (EIA) and confirmed by immunoblot. HCV RNA presence was 
investigated by reverse transcription-polymerase chain reaction (RT-PCR), and a reverse hybridization test of the 
amplifications was used for the genotyping. 
Results: The most frequently encountered genotypes were I b  (48.1%), l a  (21.3%) and 3a (11.1%). HCV genotypes l a  
(42.8%) and 3a (20.6%) were the most prevalent genotypes in IVDU patients, while I b  was the most frequent in  patients 
with unknown risk factors (62.0%), transfused patients (68.1%) and hemodialyzed patients (50.0%). Mixed infections were 
detected in  nine cases (4.1%); three appeared in IVDU patients (4.7% of the total IVDUs), two in transfused patients (4.5%) 
and four (50%) in  patients with unknown risk factors. No statistically significant differences were found in average ages 
of the IVDU patients with different genotypes. Non-IVDU patients having genotype 3a presented the lowest average age 
of all. No significant statistical differences were observed in alanine arninotransferase levels among patient groups with 
different genotypes ( p 0 . 0 5  in  all cases). Subtype I b  was present in six of the seven cases of cirrhosis (85.7%) and in  
nine of the 18 cases of active chronic hepatitis (50.0%). 
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INTRO D U CTlO N 
Since the discovery of the hepatitis C virus (HCV) in 
1989 by investigators at Chiron Corporation [l], a great 
deal of information about the genetic diversity of HCV 
has appeared in world literature. The first evidence of 
t h s  diversity arose &om the comparison of a Japanese 
isolate (HCV J1) and an American one (HCV-1) [2], 
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which revealed differences in the NS3 and NS4 
regions. Later on, differences were demonstrated in the 
NS5 [3] and envelope [4] regions, suggesting the 
existence of multiple HCV types. 
The immediate consequence of discovering the 
existence of HCV genotypes was the investigation of 
their relation to varied aspects of the infection. One of 
the aspects most studied has been the geographic distri- 
bution of the different genotypes, which have been 
found to be widely spread. Ths is especially true of 
genotype Ib, which seems to have the greatest world- 
wide prevalence [5]. However, regional dfferences in 
genotype dmribution have been observed. In Japan, 
China and Taiwan, genotypes lb, 2a and 2b constitute 
the vast majority of variants found [5,6], genotype l a  
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being very infrequent. In contrast, in southeast Asia 
genotypes l a  and 3 are frequently found [7]. Although 
the information available on genotype dstribution in 
Ah-ica is limited, it seems that genotype 4 predominates 
in wide zones ofthis continent [6,8,9]. However, South 
Ah-ica constitutes an exception, as genotype 5 is the 
most frequent variety there [6,10,11]. In Occidental 
countries (Europe, the USA and Australia) and in 
South America genotypes 1, 2 and 3 are the most 
prevalent [5,6,8,12-141. 
Another aspect studied has been the relation of 
prevalences to risk factors, with hfferences being 
revealed by the studies performed. Okamoto et al [7] 
found hfferent prevalences of genotypes l b  and 2a in 
blood donors and Japanese patients with non-A, non- 
B hepatitis. Driesel et al [15] described an elevated 
prevalence of type 3a in IVDU patients. 
The objective of our study was to ascertain the 
prevalence of different HCV genotypes in our health 
area, as well as the possible influence of risk factors on 
their distribution and their relation to hepatic disease. 
PATIENTS AND METHODS 
In this study, 216 patients diagnosed as having hepatitis 
C were included. All of them presented antibodies 
against HCV (anti-HCV) and HCV RNA detectable 
in sera by reverse transcription-polymerase chain 
reaction (RT-PCR). Liver biopsy was performed in 37 
patients. 
The distribution of patients by risk factors was as 
follows: 63 (29.1%) were intravenous drug users 
(IVDUs) (30.5k4.6 years), 44 (20.3%) had received 
transfusions (48.3k14.9 years) and 30 (13.8%) were 
hernodialyzed (52.4k15.5 years), and in 79 cases 
(36.5%) no known risk factor was found (55.6k15.4 
years). All patients underwent testing for the presence 
of HBs  antigen and IgM against hepatitis A virus (IMx, 
Abbott Laboratories, Chicago, IL, USA); the results 
were negative in both cases for all subjects. 
A second-generation enzyme immunoassay (EIA) 
(Abbott Laboratories, Chicago, IL, USA) was used to 
screen for antibodies against HCV. Immunoblot 
(Deciscan HCV, Sanofi Diagnostics Pasteur, Marnes-la- 
Coquette, France) was used to confirm antibodies 
against HCV This test uses recombinant proteins 
derived from the core (Cl) and NS3 regions, and 
synthetic peptides derived &om the core (C2) and NS4 
regions. To detect HCV RNA, an RT-PCR 
(Amplicor HCV, Roche Diagnostic Systems, Inc., 
Branchburg, NJ, USA) was used. A reverse hybridiza- 
tion test of the amplification obtained by RT-PCR 
(INNO-LiPA HCV, Innogenetics, Belgium) was used 
for HCV genotyping. Specific oligonucleotide probes 
derived &om the non-codmg region 5‘ are immobi- 
lized on nitrocellulose strips by a poly-T glue. The 
amplifications, previously marked with biotin, are 
incubated with the strips at 50°C to permit their 
hybridization with the bound probes. After washing, 
they are incubated with streptavidin conjugated with 
alkaline phosphatase at room temperature. Color 
development is performed by addition of nitroblue 
tetrazolium (NBT) and bromochloroindol phosphate 
(BCIP). Each strip has a total of 15 bands. The first is 
used as a control of the adhtion of conjugate. The 
second contains a universal probe which hybridizes 
with the amplifications of any genotype. The following 
13 bands allow differentiation of the following HCV 
genotypes and subtypes according to the scheme of 
Simmonds et al [16]: 1, la, lb, 2, 2a/2c, 2b, 3a, 3b, 4a 
and 5a. AU tests were performed according to the 
manufacturers’ instructions. 
Statistical analysis of the results was performed by 
the SAS program for personal computers (SAS Institute 
Inc., Cary, NC, USA). Fisher’s exact test (two-tail) was 
used for comparison of proportions in the standard 
two-way contingency tables. Non-parametric tests 
(ANOVA-based ranks) were used in comparison of 
measurements. Values of p <  0.05 were considered 
statistically significant. 
RESULTS 
The dominant genotype was type 1, found in 164 of 
the patients studied (75.9%); the next most frequent 
was 3a, present in 24 patients (1 1 .l%) (Table 1). Geno- 
types 4a and 2 were seldom found, being present in 
only eight (3.7%) and two (0.9%) patients respectively. 
In nine cases (4.1%), the genotype was impossible to 
determine with the test used. Within genotype 1 the 
greatest prevalence corresponded to subtype lb, present 
in 104 patients (48.1%), whde subtype l a  was found in 
46 patients (21.3%). In 14 cases (6.4%) classified as 
genotype 1 it was impossible to determine the subtype. 
Likewise, in one of the two patients in whom genotype 
2 was found, the subtype could not be determined, and 
the remaining case belonged to subtype 2a/2c. A mixed 
infection was found in nine patients (4.1%): in one case 
with genotypes 1 and 2, four cases with subtypes l a  and 
lb, and four cases with genotypes l a  and 4a. 
Table 1 shows genotype distribution according to 
risk factors. Genotype 1 was dominant in all groups, 
with percentages varying from 60.3% in the IVDU 
patients to 100% in the hernodialyzed patients. Analysis 
of the distribution of subtypes l a  and l b  by risk factor 
showed that the subtype predominant in IVDU patients 
was l a  (42.8%). However, subtype l b  was the most 
prevalent in patients of unknown risk (62.0%) and in 
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Table 1 Genotype dlstribution by risk factors 
IVDU Transfused Hemodialysis Unknown Total 
Genotype No. (‘h) No. (‘YO) No. (%) No. (%) No (%) 
1 
1-NS 
13 
l b  
2 
2-NS 
2a/2c 
3 a  
4a 
NG 
Mixed 
l a + l b  
la+4a 
1 + 2  
Total 
38 ((60.3) 
1 l(l.5) 
27 (,42.8) 
10 (15.8) 
1 (1.5) 
1 (1.5) 
13 (20.6) 
5 (7.9) 
3 (4.7) 
3 (4.7) 
3 (4.7) 
63 (100) 
37 (84.0) 
3 (6.8) 
30 (68.1) 
4 (9.0) 
1 (2.2) 
1 (2.2) 
I (2.2) 
1 (2.2) 
2 (4.5) 
2 (4.5) 
2 (4.5) 
44 (100) 
30 (100) 59 (74.6) 
3 (10.0) 7 (8.8) 
12 (40.0) 3 (3.8) 
15 (50.0) 49 (62.0) 
10 (12.6) 
2 (2.5) 
4 (5.0) 
4 (5.0) 
1 (1.2) 
1 (1.2) 
30 (100) 79 (100) 
2 (2.5) 
164 (75.9) 
14 (6.4) 
46 (21.3) 
104 (48.1) 
2 (0.9) 
1 (0.4) 
l ( 0 . 4 )  
24 (11.1) 
9 (4.1) 
0 (4.1) 
8 (3.7) 
4 (1.8) 
4 (1.8) 
1 (0.4) 
216 (100) 
l-NS, 2-NS=genotypes 1 or 2 non-subtypeable with the test used. 
NG=noii-genotypeable with the test used. 
patients with blood-transfusion antecedents (68.1%). In 
the 30 hernodialyzed patients the prevalence of subtype 
l a  was 40.0% and that of subtype l b  was 50.0%. O n  
comparing the prevalence of subtypes l a  and l b  in the 
different risk groups studied, we found that the preva- 
lence of subtype l a  was significantly higher in IVDU 
patients (42.8%) than in patients with transfusion ante- 
cedents (9.0%) (p<O.O01) or in those with unknown 
risk factors (3.8%) (p<<O.OOl). In these last two groups, 
subtype l b  predominated. In the rest of the com- 
parisons, no statistically significant differences ( p >  0.05) 
were found. Likewise, when the prevalence of geno- 
type 3a in IVDU patients (20.6%) was compared with 
that in unknown risk factor patients (12.6%), no statis- 
tically significant differences (p=0.253) were found. 
However, comparing type 3a prevalence in IVDU 
patients (20.6%) with that in non-IVDU patients 
(7.6%) did yield statistically significant differences 
( p  = 0.01 6). 
O n  the other hand, patients with genotype 3a 
presented the lowest average age (32.7k8.1 years). In 
addition, genotype 3a was associated with lower 
average age than that of patients with genotype 1 non- 
subtypeable (54.7k14.9 years), genotype l b  (53.1 
k15.8 years) and mixed genotype l a + l b  (61.2k11.3 
years) (p<0.05 in all cases) (Table 2). Subtype l a  was 
detected in a younger age group (37.95 15.5 years) than 
was subtype l b  (p<0.05). In addition, the relation 
between genotypes and age in IVDU and non-IVDU 
patients was analyzed. Non-IVDU patients having 
genotype 3a showed lower average age (36.4k9.4 
years) than non-IVDU patients infected with other 
genotypes. Furthermore, type 3a was associated with a 
lower average age than infection with genotype l b  
(55.5k14.6 years) (p<0.05). However, no statistically 
significant differences were found between the average 
ages of the IVDU patients with the different genotypes 
(Table 2). 
O n  the other hand, we analyzed the relationship 
between genotypes and ALT levels in patients with 
Table 2 Average age of patients grouped by genotype 
IVTIU Non-IVDU Total 
Mean2 SII Mean f SL> Mean k SII 
Genotvnes (no.) (no.) (no.) 
1 -NS 
l a  
l b  
2-NS 
2a/2c 
33 
4a 
NG 
l a + l b  
la+4a 
1 +2  
T o t l  
28 (1) 
30.624.6 (27) 
30.424.1 (10) 
- 
30 (1) 
29 625.6 (13) 
34.222.3 (5) 
27.6r5.5 (3) 
31.6ki .5  (3)  
~ 
- 
30.5k4.6 (63) 
56.8k13.3 (13) 
48.2k19.S (19) 
.5.5.52 14.6 (94) 
32 (1) 
36.4k9.4* (11) 
53.6+11.1 (3)  
49.5514.1 (6) 
61.2k11.3 (4) 
42 (1) 
47 (1) 
52.9215.5 (153) 
54.7k14.9 (14) 
37.9k15.5 (46) 
53.1k15.8 (104) 
32 ( I )  
30 (1) 
32.7+8.1** (24) 
41.5k11.8 (8) 
42.2215.8 (9) 
61.2211.3 (4) 
34.226.8 (4) 
47 (1) 
46.4k 16.7 (216) 
l-NS, 2-NS=genotypes 1 or 2 non-subtypeable with the test used. 
NG=iion-genotypeable with the test used. 
*p < 0.05 type 3a versus type lb. **p < 0.05 type 3a vcrsus I-NS, 
versus lh, versus la+lb.  
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Table 3 Patients with pathologic ALT levels and average 
ALT levels by genotype 
DISCUSSION 
ALTb 
Genotvaes” No. MeankSD 
1-NS 12 166.9k 152.3 
l a  33 116.2k66.5 
l b  85 125.1k85.5 
2a/2c 1 48 
3a 23 148.4k81.9 
4a 5 203.4 f 208.0 
NG 7 98.0k35.1 
l a + l b  4 155.0k77.2 
la+4a 3 149.3k97.7 
’l-NS=genotype 1 non-subtypeahle with the test used. 
NG=non-genotypeable with the test used. 
bAverage ALT levels in patients with elevated ALT (J < 0.05 in all 
cases). 
Table 4 Distribution of hepatic biopsy patterns by 
genotype 
C H  M C  PCH ACH Cirrhosis Carcinoma GH 
Genotype No No N o  No No. N o  No 
1-NS 
l a  
l h  
2-NS 
3a 
4a 
l a + l b  
la+4a 
Total 
~~ 
3 
1 2 1  1 
2 1  9 6 1 
1 
1 2  1 
1 
1 1 
2 
1 3 6 1 8  7 1 1 
C H  = chronic hepatitis of non-specified histologic degree; 
MC=minimal changes; PCH =persistent chronic hepatitis; 
ACH =active chronic hepatitis; GH =granulomatous hepatitis; 
LNS,  2-NS=non-subtypeahle with the test used. 
pathologic levels of ALT. No significant differences 
were found (p>0.05 in all cases) when the ALT levels 
were compared in the same genotype groups (Table 3). 
Liver biopsy was performed in 37 patients. In 18 
(48.6%) of these, a pattern of active chronic hepatitis 
was found, in seven (18.9%) hepatic cirrhosis, in six 
(16.2%) persistent chronic hepatitis, and in another 
three only minimal changes (8.1%). Finally, one case 
each of hepatocarcinoma, of granulomatous chronic 
hepatitis (probably due to toxicity through isoniazid) 
and of non-classified chronic hepatitis was found. Table 
4 presents the distribution of histologic patterns 
according to genotype. Genotype l b  was found in six 
of the seven cases of cirrhosis (85.7%) and in nine of 
the 18 cases (50.0%) of active chronic hepatitis. 
Our results show that in the Spanish population the 
highest prevalence corresponded to genotype lb, with 
48.1% of the cases, followed by genotype la, with 
22.3%, and genotype 3a, with 11.1%. These data show 
the greater prevalence of genotype l b  in Spain, just as 
in other Occidental countries [5,6,17,18], apart kom 
the USA [5] and the north of Europe [6,1Y] where 
genotype l a  is the most frequently described. In 
contrast to our results, Bravo et al [lY] found genotype 
l a  to be the most prevalent, although this difference 
could be due to the small number of non-IVDU 
patients in their study (18 cases). On the other hand, 
although in our study genotype 3a was the third most 
frequent (following types l b  and la), its prevalence was 
lower than that found in other European countries such 
as Scotland [12], Sweden [19] or France [18], where 
genotype 3a prevalence is over 20%. 
Genotype 2 is present only rarely in our health 
area. The presence of genotype 4a among Spanish 
people (eight cases, 3.7%) is worth noting, as it is rarely 
described in countries ofwestern Europe [6, 8, 12, 181. 
The presence of infection by more than one geno- 
type was inkequent in our study (nine cases, 4.1%), in 
contrast to the results of Bravo et a1 [20], who found 
43.8% multiple infections. Mixed infections are rarely 
mentioned in the literature, and the majority of authors 
report multiple infection percentages similar to ours 
[17,18,21,22]. However, the significance of multiple 
infections is debatable: on the one hand, a large number 
of mixed patterns are due to cross-reactions, while on 
the other hand, current genotyping techniques do not 
detect multiple infections reliably and tend to identifj. 
principally the dominant genotypes [23]. 
On the other hand, an association of some geno- 
types with specific risk groups seems to exist. In Japan 
Okamoto et al [7] found genotype l b  (I11 of Okamoto) 
to be more prevalent in patients with non-A, non-B 
hepatitis. These authors also found genotype l a  to be 
more 6-equent in hemophiliacs, attributing this to the 
US origin of the coagulation factors received. In a group 
of German patients, Driesel et al [15] found genotype 
l b  to be the most frequent among all the patients, with 
an elevated prevalence of genotype 3a in the IVDU 
group. In our study we have found a clear distribution 
of genotypes according to risk factors: among patients 
of unknown risk and those with blood-transfusion 
antecedents, genotype l b  was the most prevalent (62.0% 
and 68.1%, respectively); among hemodialyzed patients 
no statistical differences were found between genotypes 
l a  and Ib (40.0% and 50.0% respectively), while among 
IVDU patients genotypes l a  (42.8% of all cases) and 3a 
(21.6%) were the most prevalent. 
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The low prevalence of genotype 3a in IVDU 
patients found both in our study and in that of Bravo 
et al [20] (11.5%) starids out in contrast to the preva- 
lence observed in other nearby European countries 
such as France (63%) [18] and Italy (64.3%) [21]. 
Similar differences are found if we compare the preva- 
lences of genotype 3a among the non-IVDU patients 
of these countries with our results. We feel that the low 
prevalence of type 3a compared with the levels existing 
in other European countries may be due to the later 
introduction of this genotype into Spain. This could be 
supported by the fact that patients having genotype 3a 
presented the lowest average age (32.728.1 years), 
whether the totality of patients studied is considered or 
the non-IVDU (36.429.4 years) and IVDU (30.6-+ 
5.6) patient groups are analyzed separately. 
The discovery of the genetic diversity of HCV 
gave rise to the hypothesis that the greater or lesser 
severity of the clinical picture and its evolution were 
related to specific genotypes [24]. The studies per- 
formed to date are not: conclusive. McOmish et al [13] 
found a greater frequency of abnormalities of hepatic 
function in patients infected with type 3 than in those 
infected with types 1 and 2, although they doubt the 
true pathogenic significance of this fact. Dusheiko et a1 
[S] suggest the association of genotype 1 with more 
serious histologic lesions in the liver. In contrast, other 
authors [25] suggest that a relation between genotypes 
and severity of hepatic disease is not very likely. On the 
other hand, although the frequency with which 
distinct degrees of histologic lesions are found varies 
among the different studies published [17,26-281, in 
conjunction persistent chronic hepatitis (PCH) and 
active chronic hepatitis (ACH) are the most frequent 
lesions, followed by cirrhosis [29]. In our study, ACH 
was the most frequent (18 of 37 cases), followed by 
cirrhosis (seven cases), but PCH was found in only five 
cases. Genotype l b  infection has also been frequently 
associated with the most severe histologic lesions of the 
liver (especially cirrhosis and hepatocellular carcinoma) 
[22,24,30,31]. We have found similar results, as the six 
cirrhosis patients were infected by genotype lb. 
However, given that genotype l b  is predominant in 
our health area, it is to be expected that this genotype 
would appear with greater frequency in this type of 
histologic lesion. In any case, it is important to point 
out that all the patients with hepatic cirrhosis presented 
genotype lb. 
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